Vontobel Holding Ltd. Cuts Stake in Allogene Therapeutics, Inc. $ALLO

Vontobel Holding Ltd. trimmed its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 81.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 34,000 shares of the company’s stock after selling 151,646 shares during the quarter. Vontobel Holding Ltd.’s holdings in Allogene Therapeutics were worth $38,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ALLO. Goldman Sachs Group Inc. boosted its position in shares of Allogene Therapeutics by 177.9% during the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock valued at $8,547,000 after buying an additional 3,747,397 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in shares of Allogene Therapeutics by 34.9% during the first quarter. Frazier Life Sciences Management L.P. now owns 3,868,750 shares of the company’s stock valued at $5,648,000 after buying an additional 1,001,000 shares during the last quarter. Jane Street Group LLC boosted its position in shares of Allogene Therapeutics by 578.7% during the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock valued at $1,630,000 after buying an additional 952,158 shares during the last quarter. Aberdeen Group plc boosted its position in shares of Allogene Therapeutics by 138.0% during the first quarter. Aberdeen Group plc now owns 867,250 shares of the company’s stock valued at $1,266,000 after buying an additional 502,868 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of Allogene Therapeutics during the first quarter valued at $706,000. 83.63% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ALLO shares. Wall Street Zen cut Allogene Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Allogene Therapeutics in a research report on Friday, October 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Allogene Therapeutics in a research report on Wednesday, October 8th. Finally, JMP Securities reissued a “market perform” rating on shares of Allogene Therapeutics in a research report on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Allogene Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $8.44.

Allogene Therapeutics Stock Up 3.3%

NASDAQ ALLO opened at $1.27 on Thursday. The stock’s 50-day moving average price is $1.18 and its 200-day moving average price is $1.27. Allogene Therapeutics, Inc. has a 52 week low of $0.86 and a 52 week high of $3.78. The company has a market capitalization of $281.79 million, a P/E ratio of -1.14 and a beta of 0.43.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.05. Research analysts anticipate that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).